Influence of Early and Late Zoledronic Acid Administration on Vertebral Structure and Strength in Ovariectomized Rats by unknown
LABORATORY INVESTIGATIONS
Influence of Early and Late Zoledronic Acid Administration
on Vertebral Structure and Strength in Ovariectomized Rats
Julienne E. M. Brouwers Æ Bert van Rietbergen Æ
Mary L. Bouxsein
Received: 16 June 2008 / Accepted: 2 July 2008 / Published online: 19 August 2008
 The Author(s) 2008. This article is published with open access at Springerlink.com
Abstract An annual infusion of zoledronic acid (ZOL)
reduces fracture risk in osteoporotic patients. Previously, we
showed that a single ZOL injection inhibited changes in bone
microstructure and strength in rat tibiae after ovariectomy.
Here, we determined the effects of a single ZOL injection as
preventive and restorative treatment on the bone micro-
structure and strength in lumbar and caudal vertebrae of
ovariectomized (OVX) rats. Twenty-nine female 35-week-
old Wistar rats were divided into four groups: SHAM-OVX
(n = 9), OVX (n = 5), OVX and early ZOL (n = 8), and
OVX and late ZOL (n = 7). ZOL was given once (20 lg/kg
body weight s.c.) at OVX in the early ZOL group and
8 weeks later in the late ZOL group; rats were killed
16 weeks after OVX. Trabecular and cortical bone mic-
roarchitecture were measured in lumbar (L3) and caudal
(Cd6) vertebrae using micro-computed tomography, and
compressive mechanical properties were determined in L3
vertebrae. Compared to SHAM-OVX, OVX rats had sig-
nificantly lower BV/TV; SMI, Tb.N, Tb.Sp, and Conn.D
tended to be deteriorated in lumbar vertebrae, while both
ZOL groups did not differ from the SHAM-OVX group.
Both ZOL groups had significantly higher BV/TV than
OVX; the early ZOL group also had significantly lower SMI
and higher Tb.Th. OVX tended to decrease mechanical
properties, while early and late ZOL treatment inhibited
OVX-induced degeneration. Neither OVX nor ZOL induced
changes in the trabecular microarchitecture of caudal ver-
tebrae. In summary, in adult rats a single ZOL injection
inhibited OVX-induced changes in lumbar vertebral bone
microarchitecture and strength.
Keywords Bisphosphonate  Bone architecture/
structure  Osteoporosis  Animal model
Bisphosphonates inhibit bone resorption and are commonly
used to treat osteoporotic patients. They slow the process of
bone loss and reduce the risk of fracture by maintaining bone
mass and microstructure [1–3]. Zoledronic acid (ZOL) is a
potent bisphosphonate that has recently been shown to sig-
nificantly reduce fracture risk in osteoporotic patients who
received once-yearly doses [4, 5]. As the number and depth of
in vivo analyses in patients are limited, animal research is
ongoing to further elucidate the effects of ZOL on skeletal
fragility [6–9]. Previously, we showed in a longitudinal study
of adult rats that a single injection of ZOL at the time of
ovariectomy (OVX) inhibited OVX-induced deterioration of
bone microstructure and strength in the proximal tibiae for up
to 16 weeks [10]. Furthermore, a single injection of ZOL
8 weeks after OVX inhibited further deterioration of the bone
microstructure and strength in rat tibiae compared to untreated
OVX rats. Other studies have shown that weekly injections of
ZOL inhibit changes in bone microstructure and strength in rat
vertebrae after OVX [8, 9]. However, it is not known to what
extent a single dose of ZOL is able to inhibit and restore
OVX-induced loss of bone mass, structure, and strength in rat
vertebrae.
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Most studies in rats conducted to determine bone
changes induced by OVX and/or the efficacy of pharma-
cological intervention evaluate skeletal sites with red
(hematopoietic) marrow, such as the proximal tibia and
lumbar vertebra. Yet, bone sites with yellow (fatty) mar-
row, such as the distal tibia and caudal vertebra, are known
to have different cell composition from red marrow bone
sites and may respond differently to estrogen depletion
[11]. Also, caudal vertebrae in rats are subject to a different
loading environment from other vertebrae, which may also
affect the response to OVX and/or drug intervention.
The goal of this study was to determine the effects of a
single ZOL injection as a preventive and restorative
treatment on bone microstructure and strength in lumbar
vertebrae of OVX rats. Additionally, we assessed whether
lumber and caudal vertebrae respond similarly to OVX
and/or ZOL treatment in terms of bone microarchitecture.
Methods
Twenty-nine female 35-week-old Wistar rats were used
from a previous study [10]. In brief, rats were divided into
four groups based on weight: SHAM-OVX (n = 9), OVX
(n = 5), OVX and early ZOL (n = 8), and OVX and late
ZOL (n = 7). Sample size, calculated for the previously
conducted longitudinal study, was nine per group. How-
ever, the number of animals was lowered and differed
between groups due to nonsuccessful OVX, determined
after death based on uterine weight. All rats underwent
OVX at week 0; the SHAM-OVX group underwent a sham
operation. The early ZOL group received ZOL at a single
dose of 20 lg/kg body weight s.c. at the time of OVX. The
dose was chosen based on a dose–response study in rats, in
which 20 lg/kg body weight was found to be most effec-
tive [12]. The late ZOL group received the same single
dose 8 weeks after OVX. Rats were killed 16 weeks after
OVX by exsanguination.
After death, whole lumbar (L3) and caudal (Cd6) ver-
tebrae were dissected, soaked in 0.9% saline solution
gauze, and frozen at -20C. This study was approved by
the Animals Ethics Committee of the University of Ma-
astricht, the Netherlands. ZOL was kindly provided as the
disodium salt hydrate by Novartis Pharma (Basel, Swit-
zerland) and dissolved in a saline vehicle prior to injection.
Assessment of Vertebral Microarchitecture
L3 and Cd6 vertebrae were thawed to room temperature
and scanned using a high-resolution desktop microtomo-
graphic imaging system (microCT40; Scanco Medical,
Bruetisellen, Switzerland) at an isotropic voxel size of
16 lm (55 kV, 145 lA, 500 projections per 180 degrees,
200 ms integration time) and 12 lm (55 kV, 145 lA, 500
projections per 180 degrees, 200 ms integration time),
respectively. A smaller voxel size was chosen for the
caudal vertebrae as their size, and therefore volume of
interest, is smaller than lumbar vertebrae. After scanning,
samples were frozen again until mechanical testing. Images
were subjected to a gaussian filter and binarized
(sigma = 0.8, support = 1, threshold = 32% of maximal
gray-scale value) to separate bone from background [13].
For the L3 vertebrae, the trabecular region was manually
selected starting 10 slices below the cranial growth plate
and ending 10 slices above the caudal growth plate,
resulting in a trabecular region of approximately 5 mm in
the axial direction. From this region, six bone structural
parameters (bone volume fraction [BV/TV], connectivity
density [Conn.D], structure model index [SMI], trabecular
number [Tb.N], trabecular thickness [Tb.Th], and trabec-
ular separation [Tb.Sp]) were automatically determined.
Cortical bone was semiautomatically selected from com-
puted tomographic (CT) scans, using the same set of slices
as used when selecting the trabecular bone, from which the
average cortical thickness was determined. Because
the caudal vertebrae had been shown to be symmetrical in
the cranial–caudal direction, the top half of trabecular bone
was manually selected in the CT scans of the Cd6 verte-
brae, starting 10 slices below the cranial growth plate.
From this region, the same structural parameters were
determined as in the L3 vertebrae.
Static Vertebral Compression Tests
All L3 vertebrae were thawed to room temperature prior to
mechanical testing. To achieve planoparallel ends, verte-
brae were fixed in a custom-made jig. A double-blade, low-
speed diamond saw (IsoMet; Buehler, Lake Bluff, IL) was
used under constant saline irrigation to remove cranial and
caudal ends including the growth plate, resulting in a
vertebral height of about 4.2 mm. A single-blade, wafer-
ing, low-speed diamond saw was used under constant
saline irrigation to remove all posterior pedicles and pro-
cesses. Anterior elements were clipped off, resulting in an
isolated vertebral body. After sawing, the exact vertebral
height was measured using a caliper. Vertebrae were kept
frozen in a 0.9% saline solution until mechanical testing.
After thawing, vertebrae were compressed at a constant
displacement rate (3 mm/min) until failure (Synergie 100;
MTS Systems, Eden Prairie, MN). Displacement was
measured from the actuator displacement transducer of the
testing machine and corrected for stiffness of the testing
system. From the force–displacement curve, the following
mechanical parameters were determined: (1) stiffness,
calculated as the slope in the linear region between 40%
and 80% of the maximum force; (2) ultimate load, defined
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as the maximum load; (3) displacement at ultimate load;
and (4) energy to ultimate load, defined as the area under
the curve until ultimate load.
Data Analysis
All parameters were compared between groups using
analysis of variance (ANOVA) with Bonferroni’s post-hoc
test comparing all groups with each other. A two-way
ANOVA was done to determine whether the response to
OVX and ZOL was different between the L3 and Cd6
vertebrae. P \ 0.05 was considered significant.
Results
Effects of OVX and ZOL on Lumbar Vertebral
Microarchitecture
Compared to SHAM, OVX rats had a significantly lower
BV/TV in L3 vertebrae (Fig. 1). SMI, Tb.N, Tb.Sp, and
Conn.D were also substantially deteriorated in the OVX
group; however, these differences did not reach signifi-
cance. Both ZOL groups had significantly higher BV/TV
than OVX; the early ZOL group also had significantly
lower SMI and higher Tb.Th compared to OVX. Trabec-
ular microarchitecture did not differ between the SHAM-
OVX and ZOL-treated groups, except for Tb.Th, which
was significantly higher in the early ZOL group than in the
SHAM-OVX group. Trabecular architecture did not differ
between the early and late ZOL groups. Cortical thickness
did not differ between all groups.
Effects of OVX and ZOL on Vertebral Compressive
Properties
Compressive stiffness and ultimate load were lower in
OVX compared to other groups, though this did not reach
statistical significance (Fig. 2). There was a trend for both
the early and late ZOL groups to have slightly higher
stiffness and failure load than the SHAM-OVX group.
Displacement at ultimate load was similar in OVX and
SHAM groups, while it tended to be lower in both ZOL
groups. No differences were observed in energy to failure.
Comparison Between Response to OVX and ZOL
in Lumbar and Caudal Vertebrae
In the Cd6 vertebrae, trabecular architecture did not differ
between groups (Fig. 3). The response to OVX was sig-
nificantly different between caudal and lumbar vertebrae
for BV/TV and SMI (Pinteraction = 0.010 and 0.012,
respectively). ZOL treatment did not alter bone microar-
chitecture, which may be expected since OVX did not lead
to trabecular deterioration in the caudal vertebrae.
Discussion
In this study, we found that (1) a single ZOL injection inhib-
ited deterioration of trabecular bone microarchitecture and
strength in lumbar vertebrae of OVX rats, (2) neither OVX nor
ZOL treatment influenced microarchitecture in caudal verte-
brae, and (3) differences between early and late ZOL
treatment were not detectable by end-of-study measurements.
Fig. 1 Effect of OVX and ZOL
treatment on trabecular
microarchitecture of lumbar
(L3) vertebrae (mean ± SD).
(a) Significantly different from
OVX; (b) significantly different
from OVX-SHAM
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Previously, it was shown that 1 year of weekly injections
of ZOL inhibited OVX-induced changes in bone micro-
structure and bone strength of femora and lumbar vertebrae
of rats [7–9]. Also, in the same rats as used in this study, a
single injection of ZOL prevented deterioration of bone
microstructure and strength in tibiae of OVX rats for
16 weeks and a single injection at 8 weeks after OVX
prevented further deterioration of structure and strength
[10]. Additionally, in a dose–response study, it was shown
that a single injection can inhibit structural changes seen
after OVX in the tibia and retain mechanical properties in
the vertebra [12]. In this study, we determined that a single
injection of ZOL can inhibit changes in bone microstructure
and strength in vertebrae. Vertebrae present a clinically
relevant anatomical site for the treatment of osteoporosis.
As such, our study includes novel and relevant information
on the effects of a single ZOL injection on trabecular bone
microarchitecture and cortical thickness in lumbar as well
as in caudal vertebrae. The pattern in bone volume fraction
between the four groups in the lumbar vertebrae was exactly
the same as that seen in the proximal tibiae [10]. Also, a
significant correlation was found between all individual
values for bone volume fraction of the lumbar vertebrae and
those of the tibiae (r2 = 0.4, P \ 0.001; data not shown).
This indicates that the response to OVX and ZOL was
similar in the tibiae and the lumbar vertebrae.
Mechanical properties of lumbar vertebrae were reduced
in OVX vs. SHAM-OVX rats, while treatment with ZOL
Fig. 2 Effect of OVX and ZOL
treatment on quasi-static
compressive mechanical
properties of lumbar vertebrae
(mean ± SD)
Fig. 3 Effect of OVX and ZOL
treatment on trabecular
microarchitecture of caudal
(Cd6) vertebra (mean ± SD)
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inhibited these losses. Both stiffness and ultimate load in
the ZOL-treated groups were similar to values in the
SHAM-OVX group. Ultimate displacement tended to be
lower in both ZOL groups compared to the SHAM-OVX
and OVX groups, which could be an indication of a slightly
more brittle tissue due to increased mineralization,
although in a recent study no effect of ZOL on mineral
crystal size was determined in ZOL-treated, OVX rats [14].
In general, we conclude that both early and late ZOL
treatment resulted in overall, normal mechanical
properties.
Unique aspects of our study were that the effect of OVX
on caudal vertebrae was analyzed using micro-CT and that
the effect of ZOL treatment on OVX rats was studied in
caudal vertebrae. In contrast to the results from lumbar
vertebrae, trabecular architecture in caudal vertebrae did
not change in response to OVX and ZOL. Our results
concur with previous reports on nonresponsiveness to OVX
in caudal vertebrae [11, 15–17]. It has been suggested that
differences in marrow composition between lumbar and
caudal vertebrae play a role in responsiveness to OVX [11].
Cancellous bone turnover in yellow marrow, such as in the
caudal vertebrae, is lower than in red marrow sites, such as
in the lumbar vertebra, as evidenced by decreased osteo-
clast surface, osteoclast number, mineral apposition rate,
and bone formation rate [11]. These differences may be
related to the cellular composition and vascularity of bone
marrow. Also, it has been shown that the response to
parathyroid hormone is different between caudal and
lumbar vertebrae [15]. Altogether, this indicates that the
responses to OVX and to different drug treatments are
different in the caudal and lumbar vertebrae, rendering the
caudal vertebra less interesting as a therapeutic testing site.
Differences between early and late ZOL treatment were
not detectable by end-of-study measurements, though early
ZOL treatment had a slightly better effect on bone mor-
phology compared to late ZOL treatment. The late ZOL
group received the ZOL injection 8 weeks after OVX. It is
known that 8 weeks after OVX bone microarchitecture has
significantly deteriorated in the rat vertebra [18]. As bone
volume fraction was similar in the early and late ZOL
groups, we postulate that after ZOL treatment bone volume
fraction somewhat increased, as seen in the tibiae as well
[10], probably due to the filling of resorption cavities [19].
This study had several limitations. The tibiae of rats
were previously analyzed by in vivo micro-CT, and the
groups were found to have slightly different baseline val-
ues. Since in this study only end-point measurements of the
vertebrae were performed, it is possible that there was also
a small difference in baseline values in the vertebrae of
these rats. Previously, however, we showed in the longi-
tudinal study that these differences did not influence
overall trends between groups in the tibiae; therefore, it
was thought that overall trends in the vertebrae would be
similar as well [10]. Also, the rats were scanned several
times while living, which could have led to radiation
damage. However, we showed previously that the design of
the rat holder was such that only the scanned leg was
exposed to radiation and that no radiation damage was
found in the scanned leg after eight weekly scans [20].
Therefore, any radiation damage can be ruled out.
Another limitation to this study was the fact that we
were unable to detect significant deterioration of
mechanical properties resulting from OVX as well as
differences between early and late ZOL treatment by end-
of-study measurements. This lack of significant effect
may relate to the fact that the study was designed for
follow-up measurements, which makes the number of
samples needed lower than desirable for the present study.
For these cross-sectional measurements in the vertebrae,
sample sizes were relatively low, reducing the power of
the study to detect significant differences. However, it
should be noted that our primary question was whether a
single injection can prevent OVX-induced bone loss. We
were able to answer this question with adequate power
and statistical significance. In the current study, also a
nonsignificant difference of 10% between the early and
late ZOL groups in bone volume fraction was found. It
can be argued whether a study should be designed to
detect a small difference of 10% and whether this is
scientifically relevant. A power study indicated that with
the sample size and variance seen in bone volume fraction
of lumbar vertebrae and a generally assumed power of
80% and alpha of 0.05, a difference of 20% in mean
between the early and late ZOL groups would have been
detected. Thus, although the study did not have the power
to detect a small difference of 10%, it was adequately
powered to answer the primary question and to answer
secondary questions if the differences were large enough
to be clinically relevant (i.e., on the order of 20%). It
should also be noted that in previous studies on the
effects of weekly ZOL injections on mechanical proper-
ties, group sample sizes were 16–20, offering a higher
power to detect differences [7, 9]. Therefore, further
studies with a larger sample size are needed to distinguish
between the effects of early and late ZOL treatments on
vertebral trabecular microarchitecture and strength.
In conclusion, we showed that a single injection of ZOL
inhibits deterioration of bone microstructure and strength
in lumbar vertebrae of OVX rats, demonstrating the potent,
long-term antiresorptive effect of this therapy. These data
corroborate data from human iliac biopsies taken from
osteoporotic patients after 3 years of ZOL treatment [21].
Altogether, these positive effects on trabecular microar-
chitecture and strength likely contribute to the antifracture
efficacy of ZOL.
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